Circulating Tumor Tissue‐Modified‐Viral HPV DNA and Correlations With Disease Burden in Oropharyngeal Cancer
Authors:
Open Access
- 7 July 2025
- journal article
- research article
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 173 (4) , 911-918
Abstract
Introduction: Tumor‐tissue modified viral (TTMV)‐human papillomavirus (HPV) DNA is an increasingly utilized biomarker for patients with HPV‐mediated oropharyngeal squamous cell carcinoma (OPSCC). However, much remains to be studied regarding the quantitative importance of a positive pre‐treatment result and correlations with disease burden.Study Design: Retrospective cohort study.Setting: Single tertiary care center; January 2022 to July 2024.Methods: Patients with HPV‐associated OPSCC and baseline pre‐treatment TTMV‐HPV DNA levels were evaluated for primary tumor and lymph node disease extent on clinical imaging, exam, and surgical pathology results when applicable. Associations with log(pre‐treatment TTMV‐HPV DNA levels) were evaluated via multivariable linear regression. A commercially available TTMV‐HPV DNA test was used.Results: In total, 94 patients were included, who were 93% male, with median age of 63 years (interquartile range [IQR] 55‐70). Most patients were clinical tumor class cT1 (40%) or cT2 (38%) and clinical nodal class cN1 (77%). Surgical resection was performed in 37% of patients. Median pretreatment TTMV‐HPV level was 225 (IQR 46‐1132) fragments/mL. Independent associations were found between pretreatment TTMV‐HPV levels and clinical nodal staging (P < .001), largest lymph node dimension on pretreatment CT (r = 0.63 [95% confidence interval [CI]: 0.46‐1.2]; P < .001) and surgical pathology (r = 0.63 [0.18‐1.08; P = .01), number of metastatic nodes on CT (r = 0.52 [0.2‐0.84]; P < .001), clinical signs of extranodal extension (r = 1.66 [0.12‐3.2]; P = 0.04), and SUV‐max of lymph nodes (r = 0.16 [0.05–0.27]; P < 0.001).Conclusions: Pre‐treatment TTMV‐HPV DNA was significantly associated with lymph node disease burden in HPV‐associated OPSCC, on pre‐treatment CT, PET, and surgical pathology.Keywords
This publication has 33 references indexed in Scilit:
- Preoperative Circulating Tumor HPV DNA and Oropharyngeal Squamous Cell DiseaseJAMA Otolaryngology–Head & Neck Surgery, 2024
- Performance of Liquid Biopsy for Diagnosis and Surveillance of Human Papillomavirus–Associated Oropharyngeal CancerJAMA Otolaryngology–Head & Neck Surgery, 2023
- Association of Pretreatment Circulating Tumor Tissue–Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal CancerJAMA Otolaryngology–Head & Neck Surgery, 2022
- Peeling Back the Curtain on Circulating HPV Tumor DNA as a Pretreatment Biomarker in Oropharyngeal CancerJAMA Otolaryngology–Head & Neck Surgery, 2022
- Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV‐positive head and neck cancerInternational Journal of Cancer, 2022
- Cell‐free human papillomavirus DNA kinetics after surgery for human papillomavirus–associated oropharyngeal cancerCancer, 2022
- Oropharyngeal Cancer Incidence and Mortality Trends in All 50 States in the US, 2001-2017JAMA Otolaryngology–Head & Neck Surgery, 2021
- Epidemiology and incidence of HPV‐related cancers of the head and neckJournal of Surgical Oncology, 2021
- Performance of oral HPV DNA, oral HPV mRNA and circulating tumor HPV DNA in the detection of HPV‐related oropharyngeal cancer and cancer of unknown primaryInternational Journal of Cancer, 2021
- Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from 18F-FDG-PET/CT and circulating tumor DNAEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019